Plain-English translation of NCT04234048 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new formulation of a cancer medicine called (ST-001) in people with T-cell lymphoma—a blood cancer that hasn't responded to or has come back after previous treatments. The medication is given as an infusion directly into your vein. The study is designed to figure out what dose is safest and how well the treatment works.
is a drug that has shown promise against cancer, but older versions caused side effects that limited how much patients could take. This new formulation uses tiny particles suspended in a special solution, which researchers hope will reduce side effects and allow patients to receive higher, more effective doses.
You likely qualify if…
You likely don't qualify if…
The study has two phases. First, researchers will give the medication at increasing doses to small groups of patients to find the safest dose that works. Then, a larger group will receive the best dose found to test how well it controls the cancer. You will receive the medication as an infusion into your vein for 5 days in a row, with breaks between treatment cycles. You will have regular blood tests, imaging scans, and clinic visits to monitor your health and how you respond to the treatment.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States